First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer Clinical Trial

— Lung-TRIO  

Official title:

A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01038037
• Other study ID #: 2009-015068-32
• Status: Terminated
• Phase: Phase 2
• First received: December 22, 2009
• Last updated: December 3, 2014
• Start date: January 2010
• Est. completion date: December 2013

Study information

• Verified date: December 2014
• Source: Vejle Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Medicines AgencyDenmark: National Board of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the addition of panitumumab to standard chemotherapy in first-line treatment of advanced Non Small Cell Lung Cancer improves the treatment outcome. Patients are selected based on triple mutational status.

Description:

Advanced NSCLC holds a very poor prognosis with a moderate response rate to standard chemotherapy. The standard first-line treatment for advanced NSCLC is platinum based combination chemotherapy. The response rates are less than 30% and a substantial amount of patients will experience unnecessary toxicity in terms of e.g. nausea, vomiting, neuropathies or a considerable risk of renal toxicity. The median progression free survival is 3-4 months and consequently, the median overall survival is less than one year (Hotta et al 2007). Addition of new biological agents to standard chemotherapy regimens may improve the outcome for these patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 23
• Est. completion date: December 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed metastatic (stage IV) NSCLC

• Measurable disease according to RECIST v.1.0 2009

• KRAS, BRAF and PI3K wild type in primary tumor or metastatic tissue.

• Age =18

• PS < 2

• Adequate organ function

Haematology:

• Neutrophil count =1.5x10^9/L

• Platelet count =100x10^9/L

• Leucocyte count > 3,000/mm

Hepatic function:

• Total bilirubin = 1.5 times the upper normal limit (UNL)

• Serum transaminases = 2.5xUNL in absence of liver metastases, or = 5xUNL in presence of liver metastases

Renal Function:

• Creatinine clearance = 50 mL/min and serum creatinine = 1.5xUNL

Metabolic function:

• Magnesium = lower limit of normal.

• Calcium = lower limit of normal.

Consent to translational research studies

Written informed consent

Exclusion Criteria:

• Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = 1 year before enrollment/randomization, active severe infections or other concurrent disease.

• Known CNS metastasis (pretreatment routine assessment not required)

• Prior chemotherapy for metastatic disease

• Indication for radiation therapy or prior radiotherapy within 30 days before treatment start.

• Other malignant diseases within 5 years prior to inclusion in the study, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ.

• Other experimental therapy within 30 days prior to treatment initiation.

• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.

• Patients pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.

• Patients (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.

Study Design

Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• Carboplatin
i.v. day 1: AUC 5 x (GFR + 25) mg q3w
• Vinorelbine
i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
• panitumumab
i.v. day 1: 9 mg/kg q3w

Locations

Country	Name	City	State
Denmark	Vejle Hospital	Vejle

Sponsors (1)

Lead Sponsor	Collaborator
Vejle Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate		Up to 3 years	No
Secondary	Progression free survival		Up to 3 years	No
Secondary	Overall survival		Up to 3 years.	No